Compare TCI & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCI | BWAY |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.3M | 337.9M |
| IPO Year | N/A | 2019 |
| Metric | TCI | BWAY |
|---|---|---|
| Price | $52.36 | $17.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 1.8K | ★ 59.5K |
| Earning Date | 11-06-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 75.87 | ★ 213.09 |
| EPS | ★ 0.65 | 0.13 |
| Revenue | $48,675,000.00 | ★ $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | $76.80 | ★ $52.44 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $25.50 | $7.84 |
| 52 Week High | $51.71 | $18.18 |
| Indicator | TCI | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 75.45 | 56.31 |
| Support Level | $43.01 | $16.75 |
| Resistance Level | $45.00 | $18.18 |
| Average True Range (ATR) | 1.28 | 0.76 |
| MACD | 0.72 | 0.06 |
| Stochastic Oscillator | 93.57 | 74.69 |
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.